Skip to main content

Table 2 Result of quality assessment of included studies

From: Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review

Criteria of QHES

Whittington (2022)

Rafia (2022)

Kelton (2022)

Dijk (2022)

Jo (2021)

Jiang (2021)

Okuz (2021)

Ohsfeldt (2021)

Congly (2021)

Carta (2021)

Wu (2021)

Whittington (2020)

Target

6

7

7

7

7

6

6

7

6

7

6

7

Perspective

2

4

2

2

2

2

2

2

2

2

2

2

Estimation of variables

8

8

8

8

4

8

8

8

8

8

8

8

Subgroup analysis

1

1

1

1

1

1

1

1

1

1

1

1

uncertainty

4.5

9

9

4.5

9

9

4.5

9

9

9

4.5

9

Incremental analysis

6

6

6

6

6

6

6

5

6

6

6

6

study method

4

5

5

5

5

4

4

5

4

4

4

5

time horizon

7

7

7

7

3

4

3

7

5

5

3

6

costing

6

7

8

7

8

8

6

8

6

6

5

8

Primary short-term and long-term outcomes

5

6

6

6

6

6

5

6

5

6

6

6

Reliable and valid result

6

7

7

7

7

7

7

7

7

7

7

7

Model, method, analysis

6

8

8

8

8

8

4

8

8

8

8

8

Assumptions and limitations

4

6

4

4

6

6

5

4

6

6

6

5

biases

2

6

4

5

6

5

5

5

5

5

5

6

Conclusion

4

6

6

6

6

8

8

6

8

8

8

8

source of financing

3

3

3

3

3

3

3

3

3

3

3

3

Total score

74.5

96

91

86.5

87

91

77.5

91

89

91

82.5

95